Last reviewed · How we verify
Norepinephrine-S
At a glance
| Generic name | Norepinephrine-S |
|---|---|
| Also known as | vasopressor |
| Sponsor | Dalian Municipal Central Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Acute Hip Fracture and Spinal Anaesthesia Injection Time (PHASE4)
- Locus-coeruleus Function in Normal Elderly and AD Risk (NA)
- Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study (NA)
- Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy (PHASE2, PHASE3)
- Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on Robot-assisted Colorectal Surgery (NA)
- A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia (PHASE4)
- Cardiovascular Effects of Norepinephrine
- Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norepinephrine-S CI brief — competitive landscape report
- Norepinephrine-S updates RSS · CI watch RSS
- Dalian Municipal Central Hospital portfolio CI